Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 for Refractory Meningioma
NCT06012929Phase 2Withdrawn
- Sponsor
- University of Nebraska
- Start
- Dec 2026
- Primary completion
- Apr 2027
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of dordaviprone in meningioma, sponsored by University of Nebraska. Planned start Dec 2026; status: withdrawn.
02
Drugs
dordaviprone
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT06012929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012929.